NLRP3 molecular glue degrader with 85% CRP reduction and clean Phase 1 safety races into Phase 2 — does efficacy hold across HS, ASCVD, and gout?

Monte Rosa is a clinical-stage company developing a targeted anti-inflammatory drug for hidradenitis suppurativa, cardiovascular disease, and gout that is not yet approved.

Monte Rosa's MRT-8102, a molecular glue degrader targeting the NLRP3 inflammasome, achieved 85% median CRP reduction with no serious adverse events across 88 subjects in Phase 1. The thesis resolves on whether Phase 2 studies in hidradenitis suppurativa and cardiovascular risk confirm anti-inflammatory activity translates to clinical benefit. The primary risk is that CRP and biomarker responses in Phase 1 do not predict hard clinical endpoints, a challenge shared by prior NLRP3-targeting programs.